Warning: A non-numeric value encountered in /home/panacelalabs/public_html/wp-content/themes/Divi/functions.php on line 5607
Yakov Kogan, Chief  Executive Officer Panacela Labs, Inc

Yakov Kogan joined Panacela Labs, Inc from the date of its foundation. He holds a Ph.D. degree in Molecular Biology, as well as an M.S. degree in Biology from Moscow State University and an MBA from the University of Chicago. Also Yakov Kogan is Chief  Executive Officer of Cleveland BioLabs, Inc. (NASDAQ: CBLI) which is an innovative biopharmaceutical company developing novel approaches to activate the immune system and address serious medical needs. Yakov Kogan worked at the University of Chicago, where he led the execution of several sophisticated genome sequencing projects.

Vasily Kazey, СЕО Panacela Labs LLC

Dr. Vasily Kazey graduated from Biology Faculty of the Lomonosov Moscow State University in 2002. He had postgraduate training in the Research Institute of Neurology RAMS and Justus Liebig University (Giessen, Germany. In 2004 -2008 he managed the Lead Discovery Department at CJSC Chemical Diversity Research Institute (HTC ChemRAR). As part of the department management, he was responsible for integrated drug discovery projects run for Eli Lilly, MerckSerono, Abbott, Orion etc. Later on he continued his career at the Chemical Diversity Research Institute as the Director of Translational Research and was responsible for the launch of several innovative drugs. In 2011 he founded Exacte and was the head of bioanalytical laboratory “Exacte Labs” LLC. Vasily Kazey joined Panacela labs in 2013. Vasily Kazey co-authored more than 15 scientific publications in Russian and foreign peer-reviewed journals, the area of scientific interests – drug development, pharmacokinetics, metabolism.

Dmitry Prudnikov, MD, Chief Medical Officer

Dr. Prudnikov has over 20 years of experience in drug research and development. He held top management positions at Janssen Pharmaceuticals and executive positions several clinical research organizations (CROs) where he led dozens of clinical trials for top drug candidates. His leadership included trials leading to the approval of Topiramate, Cladribine, and Raptiva, among others. Besides his leadership within the CRO field, Dr. Prudnikov held top management roles in two early- stage biotech companies guiding clinical research from hit-to lead and on to Phase II trials.